On the evidence to date, tirzepatide produces more weight loss on average than semaglutide, the two share a similar side effect profile dominated by nausea, and neither is reliably cheaper because price is set by coverage rather than by the molecule. That is the short version. The longer version matters, because averages hide how differently these drugs behave from one person to the next, and because the cost gap most people care about is between insurance and cash, not between the two brands.
What does the head-to-head trial actually show?
For years the tirzepatide vs semaglutide question was answered by comparing separate trials, which is not a fair fight. That changed with a direct comparison. A 72-week randomized trial published in 2024 put the two drugs against each other in adults with overweight or obesity and found greater average weight loss with tirzepatide. That is the cleanest single answer available, and it points one direction.
The supporting picture is consistent. Tirzepatide’s key obesity trial, SURMOUNT-1, reported large average reductions at 72 weeks, and SURMOUNT-CN found similar results in Chinese adults. Semaglutide’s own record is strong too, and a separate trial, STEP 8, showed it clearly outperforming daily liraglutide. So both drugs work well. Tirzepatide simply tends to work somewhat harder, on average.
Do the numbers apply to a real person?
This is where the averages need a caution. Trial figures describe groups on strict protocols with dose escalation and support built in. An individual can land well above or well below the mean, and tolerance often decides the ceiling. A person who cannot get past a low dose of the stronger drug because of nausea may lose more on the drug they can actually stay on. The higher average is a reason to lean one way, not a guarantee.
What about keeping the weight off?
Both drugs raise the same hard question: what happens when you stop. The maintenance trials are blunt about it. In SURMOUNT-4, people who continued tirzepatide held onto their loss while those switched to placebo regained a substantial share. Semaglutide showed the same pattern in STEP 4. The practical read is that these are long-term treatments, not short courses, and the sustainable monthly cost matters more than any first-month deal.
How do the side effects compare?
Closer than the marketing of either suggests. The dominant complaints for both are gastrointestinal: nausea, diarrhea, vomiting, and constipation, heaviest during dose increases and usually easing as the body adjusts. The prescribing information for the tirzepatide brands, Zepbound and Mounjaro, lists the same broad category of effects along with a boxed warning about thyroid C-cell tumors seen in rodents. Semaglutide carries a comparable warning. Neither drug is clearly gentler across the board, and slower dose escalation is the usual lever for tolerability regardless of which one is chosen.
One point worth flagging: the benefit may reach beyond weight. Tirzepatide was studied in obstructive sleep apnea and improved that condition alongside weight reduction, which can matter for people weighing the two options with a specific comorbidity in mind.
Which one costs less?
This is the question with the least satisfying answer. Both list above a thousand dollars a month, and almost nobody pays list. What decides the number is the route to a price, not the choice between molecules.
| Route | What sets the number | Main limitation |
|---|---|---|
| Covered benefit | Formulary tier, deductible, coinsurance | Requires the plan to cover the category |
| Manufacturer savings card | Commercial insurance status, eligibility rules | Usually excludes government insurance |
| Manufacturer self-pay | Fixed cash price set by the maker | Conditions on refill timing and dose |
| Compounded medication | Pharmacy and provider pricing | Not an FDA-approved product |
The single most useful thing to check before comparing anything is whether the plan covers medication for chronic weight management as a category. If it does not, both drugs are excluded together and the comparison restarts on cash numbers. If it does, tier placement and prior authorization matter more than which drug is nominally pricier.
Where do savings cards and self-pay fit?
Manufacturer copay cards are commonly misread. The headline reduction usually assumes commercial insurance that already covers the drug, and people on Medicare or Medicaid are generally shut out. The self-pay programs the manufacturers now run for cash payers, along with direct services like Ro, Hims and Hers, and Henry Meds, sit in a different lane, and their sustainable price matters more than an introductory one. Read the eligibility fine print before treating an advertised figure as your figure.
Where does compounded medication sit?
Compounded semaglutide and tirzepatide are prepared by compounding pharmacies rather than made under an approved application. They are not FDA-approved products, and they have not been through the process that generated the trial evidence above. That is a genuine distinction. What they often provide is a predictable flat monthly cash price. Physician-supervised telehealth practices that publish this kind of pricing, including one comparison resource on Ozempic vs Zepbound, keep prescribing with a licensed clinician rather than selling a product off a shelf. The trade is regulatory assurance for cost predictability, and whether that trade is reasonable belongs with a prescriber who knows the case.
Key takeaways
- The direct 72-week trial gave tirzepatide the edge on average weight loss, but individual tolerance can flip that in practice.
- Side effects are similar, mostly gastrointestinal, and worst during dose increases for both drugs.
- Weight tends to return after stopping either one, so treat them as long-term therapies.
- Coverage decides cost far more than the choice between the two molecules.
See also: Automation in the Workplace
Frequently asked questions
Does tirzepatide really outperform semaglutide?
In the one direct 72-week trial that compared them, tirzepatide produced greater average weight loss than semaglutide. That is a real edge, but averages hide wide individual variation, and the better tolerated drug for one person can be the more effective choice overall.
Are the side effects different between the two?
The pattern is similar. Both are dominated by nausea, diarrhea, constipation, and vomiting, most often during dose increases. Neither has a clearly gentler profile in a way that holds for everyone.
Which one costs less per month?
Neither reliably. Both list above a thousand dollars a month, and what a person pays depends on coverage status and which self-pay or savings route applies far more than on which molecule is chosen.
Is compounded semaglutide or tirzepatide the same as the brand?
No. Compounded versions are prepared by a compounding pharmacy and are not FDA-approved products. They may contain the same active molecule but have not gone through the approval process behind the published trial evidence.
Does weight come back after stopping?
For both drugs, stopping is usually followed by partial regain. Trials of continued treatment showed maintained loss while on the medication and regain after withdrawal, which is why these are treated as long-term therapies.
